Organization
Gannex Pharma
Aliases
Gannex Pharma Co., Ltd.
7 clinical trials
Clinical trial
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary CholangitisStatus: Completed, Estimated PCD: 2024-03-13
Clinical trial
A Phase 1, Open-Label, Drug-Drug Interaction, Study to Evaluate the Effect of ASC42 on the Pharmacokinetics of Atorvastatin Tablets in Healthy Volunteers (HVs)Status: Completed, Estimated PCD: 2022-08-23
Clinical trial
An Open-Label, Multicenter, Single-Arm Phase 1 Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61 in Subjects With Advanced Solid TumorsStatus: Recruiting, Estimated PCD: 2024-12-20
Clinical trial
A Phase II, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Subjects With Nonalcoholic Steatohepatitis (NASH)Status: Recruiting, Estimated PCD: 2025-05-10
Clinical trial
A Seamless Phase 2a/2b, Double-Blind, Randomized, Multicenter, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41, a Thyroid Hormone Receptor β Agonist, in Adults With Nonalcoholic Steatohepatitis (NASH)Status: Withdrawn, Estimated PCD: 2024-11-10
Clinical trial
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC47 Injection for Subcutaneous Use in Healthy SubjectsStatus: Not yet recruiting, Estimated PCD: 2024-12-01